

# Leukaemia Section

## Short Communication

### t(2;9)(q12;q34) RANBP2/ABL1

Marc De Braekeleer, Nadia Guéganic, Alexandra Schifferli, Joëlle Tchinda

Cytogenetics Laboratory, Faculty of Medicine, University of Brest, France marc.debraekeleer@univ-brest.fr (MdB, NG)) Department of Hematology/Oncology, University Children's Hospital Basel, Switzerland (AS) University Children's Hospital Zurich, Switzerland (JT)

Published in Atlas Database: December 2015

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t0209q12q34RANBP2-ABL1ID1305.html>

Printable original version : <http://documents.irevues.inist.fr/bitstream/handle/2042/66089/12-2015-t0209q12q34RANBP2-ABL1ID1305.pdf>  
DOI: 10.4267/2042/66089


This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## Abstract

### Abstract

Review on t(2;9)(q12;q34), with data on clinics, and the genes involved.

**Keywords:** chromosome 2; chromosome 9; RANBP2; ABL1



GTG banding showing chromosomes 2 and 9 and the derivatives der(2) and der(9).

## Clinics and pathology

### Disease

Pre-B acute lymphoblastic leukemia

### Epidemiology

Two cases reported: a 15-year-old male (Roberts et al., 2012; Roberts et al., 2014) and a 21-month girl (Braekeleer et al., 2015).

## Evolution

Alive 23 months after diagnosis in complete remission for one case, unknown for the other.

## Cytogenetics

The t(2;9)(q12;q34) involves the RANBP2 and ABL1 genes. This fusion was first identified by RNA-sequencing in a boy with B-cell ALL (Roberts et al., 2012).

### Cytogenetics morphological

t(2;9)(q12;q34) is identified by banding cytogenetics.

### Cytogenetics molecular


FISH with a BCR-ABL probe showed 3 ABL signals. To determine the position of the breakpoints on chromosome 2, BACs located in bands 2q12.1 to 2q14.2 were used as probes in FISH experiments. A split signal on der(2) and der(9) was found with RP11-622D1, RP11-347H10, RP11-259O12, RP11-348G16 and RP11-953L12. These BAC clones overlap the RANBP2 gene and allow refinement of the breakpoint to a 25kb region covering the 5' end and the first three exons of RANBP2 (figure BAC).

## Genes involved and proteins

### RANBP2 (RAN binding protein 2)

#### Location

2q12.3



FISH with BACs RP11-953L12 (spectrum green, located in 2q12 and containing RANBP2) and RP11-83J21 (spectrum orange, located in 9q34 and containing the 3' part of ABL1) and CEP9 (in aqua) showing one fusion signal on der(2). No fusion is detected on der(9) because RP11-83J21 does not cover the 5' part of ABL1.

#### DNA/RNA

The RANBP2 (alias NUP358) gene contains 31 exons, spanning 66 kb. One major transcript with several alternative splicing variants is known.

#### Protein

The protein has 3324 amino acids and is the largest component of nuclear pore complexes. It contains an N-terminal leucine-rich region, four RAN binding domains, eight zinc-finger motifs, a SUMO E3 ligase region and a C-terminal cyclophilin A-like domain. A detailed assessment of its functions is available elsewhere in the Atlas (Di Cesare E, Lavia P. RANBP2 (RAN binding protein 2. <http://AtlasGeneticsOncology.org/Genes/RANBP2I483.html>).

### **ABL1 (v-abl Abelson murine leukemia viral oncogene homolog 1)**

#### Location

9q34.12

#### DNA/RNA

The ABL1 gene, spanning a 230kb region at band 9q34, includes the 5' alternative first exons 1b and 1a and ten common exons numbered from 2 to 11. Alternative splicing using exons 1b and 1a gives rise to mRNA of 7 and 6 kb, respectively.

#### Protein

The ABL1 protein has three SRC homology (SH) domains called SH1, SH2 and SH3, of which SH1 that has tyrosine kinase function.

The SH2 and SH3 domains are involved in protein-protein interactions, which regulate the tyrosine kinase activity; they are necessary for signal transduction function. The ABL1 protein has also three nuclear localization signal domains and three

DNA binding regions and an F-actin binding domain.

## Result of the chromosomal anomaly

### Hybrid gene

#### Description

The 3' region of ABL1 is translocated on the 5' region of RANBP2 on the der(2) and the 3' region of RANBP2 is translocated on the 5' region of ABL1 on der(9).

#### Detection

FISH detection.

### Fusion protein

#### Description

The fusion protein retains the leucine-rich domain, including a leucine zipper, located at the N-terminal of RANBP2 and the tyrosine kinase domain of the ABL1 protein.

#### Oncogenesis

The leucine-rich region of RANBP2 is predicted to mediate homo-oligomerization of the fusion protein, leading to the activation of the tyrosine kinase of ABL1.

## To be noted

Two other genes are known to fuse to RANBP2 and generate in-frame transcripts. These are ALK in inflammatory myofibroblastic tumor (Li et al., 2013;Ma et al., 2003), diffuse large B-cell lymphoma (Lee et al., 2014) and myeloid neoplasm (Lim et al., 2014;Maesako et al., 2014;Rottgers et al., 2010) and FGFR1 in myeloproliferative neoplasm (Gervais et al., 2013). In all cases, the fusion protein includes the leucine zipper portion of RANBP2 and the tyrosine kinase domain of the partner protein, leading to its activation.

## References

Braekeleer M de, Guéganic N, Schifferli A, Tchinda J.. A pediatric case of acute lymphoblastic leukemia with t(2;9)(q12;q34) RANBP2-ABL1 fusion Atlas Genet Oncol Haematol (in press)

Gervais C, Dano L, Perrusson N, Hélias C, Jeandidier E, Galois AC, Ittel A, Herbrecht R, Bilger K, Mauvieux L. A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm Leukemia 2013 Apr;27(5):1186-8

Lee SE, Kang SY, Takeuchi K, Ko YH. Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma Hematol Oncol 2014 Dec;32(4):221-4

Li J, Yin WH, Takeuchi K, Guan H, Huang YH, Chan JK. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review Diagn Pathol 2013 Sep 13;8:147

Lim JH, Jang S, Park CJ, Cho YU, Lee JH, Lee KH, Lee JO, Shin JY, Kim JI, Huh J, Seo EJ. RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia *Cancer Genet* 2014 Jan-Feb;207(1-2):40-5

Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, Zuppan C, Bridge JA. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor *Genes Chromosomes Cancer* 2003 May;37(1):98-105

Maesako Y, Izumi K, Okamori S, Takeoka K, Kishimori C, Okumura A, Honjo G, Akasaka T, Ohno H. inv(2)(p23q13)/RAN-binding protein 2 (RANBP2)-ALK fusion gene in myeloid leukemia that developed in an elderly woman *Int J Hematol* 2014 Feb;99(2):202-7

Röttgers S, Gombert M, Teigler-Schlegel A, Busch K, Gamedinger U, Slany R, Harbott J, Borkhardt A. ALK fusion genes in children with atypical myeloproliferative leukemia *Leukemia* 2010 Jun;24(6):1197-200

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J,

Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia *N Engl J Med* 2014 Sep 11;371(11):1005-15

---

*This article should be referenced as such:*

De Braekeleer M de, Guéganic N, Schifferli A, Tchinda J. t(2;9)(q12;q34) RANBP2/ABL1. *Atlas Genet Cytogenet Oncol Haematol*. 2016; 20(10):536-538.

---